Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


01.10.2018

1 Exp Brain Res
1 J Neurol Neurosurg Psychiatry
1 J Neurosci
4 Mov Disord
1 Neurology
1 Neurosci Lett
2 PLoS One
1 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Exp Brain Res

  1. PENEDO T, Polastri PF, Rodrigues ST, Simieli L, et al
    Influence of obstacle color on locomotor and gaze behaviors during obstacle avoidance in people with Parkinson's disease.
    Exp Brain Res. 2018 Sep 25. pii: 10.1007/s00221-018-5385.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  2. LERCHE S, Wurster I, Roben B, Machetanz G, et al
    Parkinson's disease: evolution of cognitive impairment and CSF Abeta1-42 profiles in a prospective longitudinal study.
    J Neurol Neurosurg Psychiatry. 2018 Sep 25. pii: jnnp-2018-318956.
    PubMed     Text format     Abstract available


    J Neurosci

  3. MATIKAINEN-ANKNEY BA, Kezunovic N, Menard C, Flanigan M, et al
    Parkinson's Disease-linked LRRK2-G2019S mutation alters synaptic plasticity and promotes resilience to chronic social stress in young adulthood.
    J Neurosci. 2018 Sep 24. pii: JNEUROSCI.1457-18.2018.
    PubMed     Text format     Abstract available


    Mov Disord

  4. GAARE JJ, Nido GS, Sztromwasser P, Knappskog PM, et al
    Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease.
    Mov Disord. 2018 Sep 5. doi: 10.1002.
    PubMed     Text format     Abstract available

  5. FABBRI M, Ferreira JJ, Lees A, Stocchi F, et al
    Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Mov Disord. 2018 Sep 27. doi: 10.1002/mds.27475.
    PubMed     Text format     Abstract available

  6. SICILIANO M, Trojano L, Santangelo G, De Micco R, et al
    Fatigue in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27461.
    PubMed     Text format     Abstract available

  7. RAMIG L, Halpern A, Spielman J, Fox C, et al
    Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27460.
    PubMed     Text format     Abstract available


    Neurology

  8. MORENO GM, Gandhi R, Lessig SL, Wright B, et al
    Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
    Neurology. 2018 Sep 26. pii: WNL.0000000000006396.
    PubMed     Text format    


    Neurosci Lett

  9. JIN L, Wan W, Wang L, Wang C, et al
    Elevated microRNA-520d-5p in the serum of patients with Parkinson's disease, possibly through regulation of cereloplasmin expression.
    Neurosci Lett. 2018 Sep 19. pii: S0304-3940(18)30640.
    PubMed     Text format     Abstract available


    PLoS One

  10. HILLER AL, Murchison CF, Lobb BM, O'Connor S, et al
    A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter?
    PLoS One. 2018;13:e0203637.
    PubMed     Text format     Abstract available

  11. MALLING ASB, Morberg BM, Wermuth L, Gredal O, et al
    Effect of transcranial pulsed electromagnetic fields (T-PEMF) on functional rate of force development and movement speed in persons with Parkinson's disease: A randomized clinical trial.
    PLoS One. 2018;13:e0204478.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  12. LUNATI A, Lesage S, Brice A
    The genetic landscape of Parkinson's disease.
    Rev Neurol (Paris). 2018 Sep 20. pii: S0035-3787(18)30806.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: